New York State Teachers Retirement System Invests $1.11 Million in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

New York State Teachers Retirement System acquired a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 24,592 shares of the company's stock, valued at approximately $1,107,000.

A number of other hedge funds also recently added to or reduced their stakes in PTGX. China Universal Asset Management Co. Ltd. grew its stake in Protagonist Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,329 shares of the company's stock valued at $510,000 after purchasing an additional 4,438 shares during the last quarter. Cavalier Investments LLC purchased a new position in Protagonist Therapeutics during the 3rd quarter worth $1,348,000. State of Alaska Department of Revenue acquired a new position in Protagonist Therapeutics during the 3rd quarter valued at about $1,512,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Protagonist Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,130 shares of the company's stock valued at $95,000 after buying an additional 379 shares during the last quarter. Finally, Louisiana State Employees Retirement System acquired a new stake in Protagonist Therapeutics in the third quarter worth about $1,282,000. 98.63% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently commented on PTGX shares. JMP Securities decreased their price objective on shares of Protagonist Therapeutics from $45.00 to $43.00 and set a "market outperform" rating for the company in a research report on Wednesday, August 7th. HC Wainwright upped their target price on Protagonist Therapeutics from $40.00 to $50.00 and gave the company a "buy" rating in a research report on Thursday, September 12th. StockNews.com raised Protagonist Therapeutics from a "hold" rating to a "buy" rating in a report on Thursday, August 8th. JPMorgan Chase & Co. lifted their price objective on shares of Protagonist Therapeutics from $39.00 to $48.00 and gave the company an "overweight" rating in a report on Thursday, July 25th. Finally, TD Cowen upgraded shares of Protagonist Therapeutics to a "strong-buy" rating in a report on Wednesday, September 25th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $53.57.

Protagonist Therapeutics Trading Down 2.9 %

Shares of NASDAQ PTGX traded down $1.38 during midday trading on Friday, reaching $46.23. 682,762 shares of the company were exchanged, compared to its average volume of 493,059. The stock has a market cap of $2.72 billion, a P/E ratio of 17.38 and a beta of 2.17. The stock has a fifty day simple moving average of $45.54 and a 200 day simple moving average of $38.09. Protagonist Therapeutics, Inc. has a 1 year low of $14.78 and a 1 year high of $48.89.

Insiders Place Their Bets

In other Protagonist Therapeutics news, CFO Asif Ali sold 14,203 shares of the firm's stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $44.49, for a total transaction of $631,891.47. Following the completion of the transaction, the chief financial officer now directly owns 34,960 shares in the company, valued at approximately $1,555,370.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CFO Asif Ali sold 14,203 shares of Protagonist Therapeutics stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $44.49, for a total transaction of $631,891.47. Following the completion of the sale, the chief financial officer now owns 34,960 shares in the company, valued at approximately $1,555,370.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director William D. Waddill sold 8,000 shares of the company's stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $45.00, for a total transaction of $360,000.00. Following the completion of the transaction, the director now owns 12,000 shares in the company, valued at approximately $540,000. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.40% of the stock is owned by company insiders.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.